Antibodies | Brain-Targeted Delivery for Alzheimer's Disease: Antibody Fusion Therapies Focused on Transferrin Receptor

This article systematically summarizes recent advances in antibody fusion proteins that achieve brain penetration via TfR-mediated receptor transcytosis for the treatment of Alzheimer's disease, providing a clear molecular design pathway and preclinical validation framework for developing highly effective and low-toxicity central nervous system biologics.

 

Literature Overview

The article, 'Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review,' published in the journal Antibodies, systematically explores strategies targeting the blood-brain barrier transferrin receptor (TfR) to enhance the brain delivery of therapeutic biomacromolecules. The article focuses on reviewing various antibody-based fusion proteins, including EPO, TNF-α inhibitors, anti-Aβ antibodies, and enzymes such as NEP, and their applications and mechanisms in Alzheimer’s disease (AD) models. The authors note that although current anti-Aβ monoclonal antibodies have been approved, their low brain penetration and tendency to cause amyloid-related imaging abnormalities (ARIA) remain clinical bottlenecks. Therefore, utilizing TfR as a 'molecular Trojan horse' to drive receptor-mediated transcytosis (RMT) of therapeutic proteins across the BBB has become a breakthrough strategy. This article comprehensively reviews representative molecular designs, pharmacokinetic characteristics, and efficacy evidence from multiple AD mouse models, offering critical references for the development of next-generation brain-penetrant biologics.

Background Knowledge

Alzheimer’s disease (AD) is a neurodegenerative disorder characterized by β-amyloid (Aβ) deposition and hyperphosphorylation of tau protein, for which there is currently no effective cure. Although anti-Aβ immunotherapies have made some progress, their clinical application is limited by the strict regulation of the blood-brain barrier (BBB), resulting in extremely low brain bioavailability of antibodies (typically <0.1% ID/g), thereby weakening therapeutic efficacy. Moreover, high-dose peripheral administration often triggers severe adverse reactions such as ARIA, associated with vascular Aβ clearance. Thus, achieving efficient and safe brain-targeted delivery remains a core challenge in AD therapy. The transferrin receptor (TfR) is highly expressed on brain microvascular endothelial cells and mediates transcytosis of endogenous transferrin, making it an ideal target for brain penetration. However, TfR-targeting strategies must balance receptor binding affinity with release efficiency to avoid receptor saturation or degradation, which could disrupt endogenous iron metabolism. The focus of this article is to systematically evaluate the feasibility of using TfR as a 'molecular shuttle' to construct bifunctional antibody fusion proteins, covering a complete pipeline from molecular design and pharmacokinetic optimization to multi-model validation, providing a systematic solution to the BBB penetration challenge.

 

 

Research Methods and Experiments

The authors employed a narrative review approach, integrating key studies from recent years in the field of brain-penetrant biologics, with a focus on analyzing the performance of various TfR-targeted fusion proteins in transgenic mouse models of AD. The study systems included several classical AD animal models such as APP/PS1, APPSAA KI, PS19, and 3xTg-AD mice, which simulate phenotypes of Aβ deposition, tau pathology, or both. Key experiments involved constructing fusion proteins (e.g., TfRMAb-EPO, TfRMAb-TNFR, TfRMAb-ScFv) and evaluating their pharmacokinetics (e.g., brain uptake, plasma half-life), pharmacodynamics (e.g., Aβ burden, pTau levels, behavioral outcomes), and safety (e.g., hematological parameters, immunogenicity, microhemorrhage). For example, after intravenous or intraperitoneal administration, drug concentrations in brain tissue were measured using radiolabeling or ELISA; changes in pathological markers were analyzed by immunohistochemistry or Western blot; and cognitive function was assessed through behavioral tests such as the Morris water maze. These data collectively support the central conclusion that 'brain-penetrant fusion proteins outperform traditional monoclonal antibodies.'

Key Conclusions and Perspectives

• The fusion protein TfRMAb-EPO achieved a brain uptake of 2% ID/g in APPSAA KI mice after subcutaneous administration—30 times higher than non-targeted antibodies—and reduced Aβ burden by 70%, demonstrating that TfR-mediated delivery can significantly enhance brain exposure of therapeutic proteins. [Data discovery] + [Implications for subsequent drug design]
• TfRMAb-TNFR significantly reduced Aβ plaques and neuroinflammation in the APP/PS1 model, with superior efficacy compared to non-penetrant etanercept, proving that targeting the brain’s TNF-α inflammatory pathway is an effective strategy for AD treatment. [Data discovery] + [Implications for subsequent mechanistic research]
• The bispecific antibody trontinemab (targeting Aβ and TfR) showed significant brain Aβ clearance in Phase I/II clinical trials with an ARIA incidence of <5%, validating that brain-penetrant designs can reduce toxicity risks associated with traditional anti-Aβ therapies. [Data discovery] + [Implications for subsequent clinical monitoring]
• Molecules such as TfRMAb-ScFv and ATV:Aβ MAb did not cause cerebral microhemorrhage, and TfRMAb-EPO did not induce erythrocytosis under chronic dosing, indicating that properly designed TfR-targeting strategies can avoid hematological toxicity associated with TfR saturation. [Data discovery] + [Implications for subsequent safety assessment]
• Besides Aβ targeting, brain-penetrant NEP and SST fusion proteins effectively degrade Aβ40, expanding the molecular toolkit for AD therapy and supporting the necessity of multi-target interventions. [Data discovery] + [Implications for subsequent drug development]

Research Significance and Prospects

This study provides a clear translational pathway for biologic development in AD: by leveraging TfR-mediated RMT strategies, therapeutic proteins can be efficiently delivered into the brain, achieving therapeutic concentrations with lower peripheral exposure, thereby significantly reducing the risk of side effects such as ARIA. This strategy is not only applicable to Aβ targeting but can also be extended to emerging targets such as tau, TREM2, and neuroinflammation, promoting the development of multi-mechanism combination therapies. Future research needs to further optimize TfR binding affinity to avoid receptor downregulation and explore immunogenicity risks of humanized antibodies. Additionally, long-term safety, optimal dosing regimens, and dynamic biomarker monitoring still require validation in larger clinical trials.

 

 

Conclusion

This article systematically summarizes the latest advances in brain-penetrant antibody fusion proteins targeting the transferrin receptor (TfR) for the treatment of Alzheimer’s disease (AD). From EPO to TNF-α inhibitors, and to the bispecific anti-Aβ antibody trontinemab, these molecules efficiently cross the blood-brain barrier (BBB) via receptor-mediated transcytosis (RMT), demonstrating significant pathological clearance and potential cognitive improvement in animal models and early clinical trials. Crucially, this design substantially reduces the risk of amyloid-related imaging abnormalities (ARIA)—a common side effect of traditional immunotherapies—addressing a core challenge in clinical translation. This study not only provides a blueprint for next-generation biologics in AD therapy but also underscores the pivotal role of brain-targeted delivery technologies in central nervous system disorders. In the future, combining precise AD animal models (e.g., APP/PS1, PS19) with efficient molecular delivery platforms may accelerate the bench-to-bedside translation, offering safer and more effective treatment options for AD patients. This review offers an important theoretical and practical framework for drug development across the neurodegenerative disease field.

 

Rachita K Sumbria and Ruben J Boado. Brain Delivery of Antibody-Derived Biologicals for Alzheimer’s Disease: An Updated Narrative Review. Antibodies.